Denu 60mg Injection

Product Details

Denu 60mg Injection contains Denosumab, a monoclonal antibody that targets and inhibits RANKL (Receptor Activator of Nuclear Factor Kappa-Β Ligand). It is primarily used for treating osteoporosis in postmenopausal women and men at high risk of fractures, as well as reducing the risk of bone-related complications in patients with cancer. By inhibiting RANKL, Denu prevents the formation, function, and survival of osteoclasts, the cells responsible for bone resorption, thereby helping to maintain bone density and strength.

Uses:

• Treatment of osteoporosis in postmenopausal women
• Reducing fracture risk in men at high risk of osteoporosis
• Prevention of skeletal-related events in patients with bone metastases from solid tumors
• Treatment of giant cell tumor of bone

Side Effects:

• Common side effects: back pain, pain in the extremities, muscle pain, and constipation.
• Serious side effects: hypocalcemia (low calcium levels), osteonecrosis of the jaw, and serious infections; patients should seek medical advice if experiencing symptoms like unusual pain or swelling.

Key Features:

• Contains Denosumab, a targeted therapy for osteoporosis and cancer-related bone loss.
• Inhibits bone resorption by blocking RANKL, helping to maintain bone density.
• Administered via subcutaneous injection, typically once every six months.
• Effective in reducing the risk of fractures and managing bone health in cancer patients.

FAQ:

1. How does Denu 60mg Injection work?
   Denu inhibits RANKL, which prevents the formation and activity of osteoclasts, thus reducing bone resorption and helping maintain bone density.
2. Who should use Denu?
   Denu is indicated for postmenopausal women and men at high risk for fractures due to osteoporosis, as well as patients with cancer at risk for skeletal-related events.
3. What precautions should I take while using Denu?
   Regular monitoring of calcium levels is essential, and patients should inform their healthcare provider about any dental issues or planned dental procedures.

References:

1. Amgen Inc. “Prolia (denosumab) injection, for subcutaneous use.” U.S. Food and Drug Administration. [Revised on 2021 Dec; Accessed on 5 Nov 2024]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535388/
2. European Medicines Agency (EMA). “Denosumab (Denu) Product Information.” [Accessed on 5 Nov 2024]. Available from: https://medlineplus.gov/druginfo/meds/a610023.html